Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally, provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: A method for controlling aggregation for HRAM comprises a processing device, using a buffer manager, to receive instructions that include smaller-sized block write instructions from a host system. The processing device, using an aggregation engine, aggregates the smaller-sized block write instructions from the buffer manager into a plurality of larger-sized write instructions. The processing device issues a burst write instruction comprising the larger-sized write instructions to the memory component via the interface. The memory component can be HRAM and the interface can be a modified DDR-L5 interface for HRAM. Other embodiments are described herein.

Abstract: Provided herein are drug implants comprising apalutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and apalutamide disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may be used for the treatment of a proliferative disease of the prostate.

Abstract: Provided herein are drug implants comprising enzalutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and enzalutamide disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may be used for the treatment of a proliferative disease of the prostate.

Abstract: Provided herein are drug implants comprising enzalutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and enzalutamide disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may be used for the treatment of a proliferative disease of the prostate.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally, provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: Provided herein are drug implants comprising enzalutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and enzalutamide disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may be used for the treatment of a proliferative disease of the prostate.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: An indication of a capacity of a CMB elasticity buffer and an indication of a throughput of one or more memory components associated with the CMB elasticity buffer can be received. An amount of time for data at the CMB elasticity buffer to be transmitted to one or more memory components can be determined based on the capacity of the CMB elasticity buffer and the throughput of the one or more memory components. Write data can be transmitted from a host system to the CMB elasticity buffer based on the determined amount of time for data at the CMB elasticity buffer to be transmitted to the one or more memory components.

Abstract: An indication of a capacity of a CMB elasticity buffer and an indication of a throughput of one or more memory components associated with the CMB elasticity buffer can be received. An amount of time for data at the CMB elasticity buffer to be transmitted to one or more memory components can be determined based on the capacity of the CMB elasticity buffer and the throughput of the one or more memory components. Write data can be transmitted from a host system to the CMB elasticity buffer based on the determined amount of time for data at the CMB elasticity buffer to be transmitted to the one or more memory components.

Abstract: An indication of a capacity of a CMB elasticity buffer and an indication of a throughput of one or more memory components associated with the CMB elasticity buffer can be received. An amount of time for data at the CMB elasticity buffer to be transmitted to one or more memory components can be determined based on the capacity of the CMB elasticity buffer and the throughput of the one or more memory components. Write data can be transmitted from a host system to the CMB elasticity buffer based on the determined amount of time for data at the CMB elasticity buffer to be transmitted to the one or more memory components.

Abstract: An indication of a capacity of a CMB elasticity buffer and an indication of a throughput of one or more memory components associated with the CMB elasticity buffer can be received. An amount of time for data at the CMB elasticity buffer to be transmitted to one or more memory components can be determined based on the capacity of the CMB elasticity buffer and the throughput of the one or more memory components. Write data can be transmitted from a host system to the CMB elasticity buffer based on the determined amount of time for data at the CMB elasticity buffer to be transmitted to the one or more memory components.

Abstract: The present invention relates to methods and systems for providing reliable power to a storage device, such as a network attached storage. In one embodiment, the storage device employs a redundant power backplane design using a DC-to-DC converter per drive in the backplane. Each drive is thus provided its own independent power interface to the power backplane. One embodiment may employ DC-to-DC converters having integrated N-channel MOSFETs to provide overcurrent and thermal protection. In addition, an embodiment may employ a staggered startup procedure to manage peak power draw.

Abstract: A kit for use in shoulder arthroplasty includes a tamp configured to form a generally oval cavity in grafting material in a glenoid vault, the tamp including a body and a forming portion shaped complementary to the oval cavity, and a glenoid component including a body having a stem portion with an oval cross section for inserting at least partially into the generally oval cavity, the stem portion configured to substantially fill the glenoid vault.

Abstract: A kit for use in shoulder arthroplasty includes a tamp configured to form a generally oval cavity in grafting material in a glenoid vault, the tamp including a body and a forming portion shaped complementary to the oval cavity, and a glenoid component including a body having a stem portion with an oval cross section for inserting at least partially into the generally oval cavity, the stem portion configured to substantially fill the glenoid vault.